WS has received research support from Incyte Corporation and Blueprint Medicines; has received consultancy fees from or participated on advisory boards for Blueprint Medicines and Incyte Corporation. PC is a former employee and stock owner of Incyte Corporation. TIG has received consultancy fees from or participated on advisory boards for Blueprint Medicines, Celgene/Bristol Myers Squibb, Cogent Biosciences, and Incyte Corporation. J-JK is a member of an entity’s Board of Directors or advisory committees for AbbVie, AOP Health, Bristol Myers Squibb, Incyte Corporation, and Novartis. CL has received consultancy fees from Blueprint Medicines, Cogent Biosciences, and Incyte Corporation. JLP has received consultancy fees from or participated on advisory boards for Astellas Pharma, Celgene/Bristol Myers Squibb, and Incyte Corporation. AR has received honoraria from, is a member of an entity’s Board of Directors or advisory committees for, and received other (travel expenses) and research funding from AOP Health, Blueprint Medicines, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Novartis; is a member of an entity’s Board of Directors or advisory committees and received research funding from AbbVie; and received honoraria and other (travel expenses) from Incyte Corporation. AMV received honoraria from and is a member of an entity’s Board of Directors or advisory committees for Bristol Myers Squibb, Incyte Corporation, and Novartis; and is a member of an entity’s Board of Directors or advisory committees for AbbVie. JG received research funding from Blueprint Medicines, Deciphera, and Incyte Corporation; received consultancy fees from or participated on advisory boards for Allakos, Blueprint Medicines, Deciphera, Incyte Corporation, and Novartis.